Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(100%)

Phase Distribution

Ph phase_2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(2)

Detailed Status

Terminated2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

terminated2100%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_2

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

NCT03717480
terminatedphase_2

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

NCT00539500

Clinical Trials (2)

Showing 2 of 2 trials
NCT03717480Phase 2

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

Terminated
NCT00539500Phase 2

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
2